Severe Psoriasis Successfully Treated with Brodalumab after Eradication of Hepatitis C Virus with Glecaprevir and Pibrentasvir: A Case Report

Ito, Michiko; Ichiyama, Susumu; Hoashi, Toshihiko; Kanda, Naoko; Iwashita, Ai; Kawamoto, Chiaki; Saeki, Hidehisa

doi:10.5021/ad.2021.33.6.593

Cited by 1 publication

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the second patient, HCV‐RNA was not detected. In the third patient, the HCV‐RNA level was 6.6 Log IU/mL and his chronic hepatitis C was completely treated with new direct‐acting antiviral agents (DAA) before the initiation of the biologic 8 …”

Section: Resultsmentioning

confidence: 99%

“…In the third patient in this study, chronic hepatitis C was completely treated with the new DAA glecaprevir and pibrentasvir before the initiation of biologic, brodalumab. Now that highly effective new DAA are available for chronic HCV, it is desirable to consult a hepatologist and eradicate HCV before the initiation of biologic therapy 8 …”

Section: Discussionmentioning

confidence: 99%

“…Now that highly effective new DAA are available for chronic HCV, it is desirable to consult a hepatologist and eradicate HCV before the initiation of biologic therapy. 8 For patients with AIDS, the advisability of using biologics should be carefully considered on the basis of risks versus benefits, and patients should be observed carefully after the initiation of treatment. 3 Although we did not use biologics for HIV antibody-positive patients in this study, we previously reported a patient with severe psoriasis and HIV infection who was successfully treated with ustekinumab.…”

Section: Discussionmentioning

confidence: 99%

“…In the third patient, the HCV-RNA level was 6.6 Log IU/mL and his chronic hepatitis C was completely treated with new direct-acting antiviral agents (DAA) before the initiation of the biologic. 8 The number of HIV antibody-positive patients was zero (0%), and there was only one HTLV-1 antibody-positive patient (0.8%). With regard to the HTLV-1-positive (×4096) patient, atypical lymphocytes were not detected in peripheral blood, and serum levels of calcium, lactate dehydrogenase, and soluble IL-2 receptor were all within normal limits, indicating that she was a HTLV-1 carrier.…”

Section: Re Sultsmentioning

confidence: 96%

See 3 more Smart Citations

Real‐world blood examination screening data before initiation of biologics for psoriasis patients

Ozaki

Ichiyama

Ito

et al. 2022

The Journal of Dermatology

Self Cite

View full text Add to dashboard Cite

Psoriasis is a chronic immune‐mediated inflammatory skin disease characterized by hyperproliferation of epidermal keratinocytes. Biologics have been available for the treatment of patients with refractory psoriasis since 2010 in Japan, and as of December 2021, 10 biologics were available. The Biologics Review Committee of the Japanese Dermatological Association for Psoriasis recommends blood examination tests for antinuclear antibodies (ANA), Krebs von den Lugen (KL)‐6, hepatitis B surface antigen (HBsAg), hepatitis B surface antibodies (HBsAb), hepatitis B core antibodies (HBcAb), hepatitis C virus (HCV) antibodies, HIV antibodies, human T‐cell leukemia virus (HTLV)‐1 antibodies, β‐D‐glucan, and the T‐cell spot (T‐SPOT) test before initiation of biologics at screening. In this study, we evaluated the use of biologics for 127 psoriasis patients and the blood examination screening data before initiation of biologics in the real‐world setting. Tumor necrosis factor inhibitors, interleukin (IL)‐17 inhibitors and IL‐23 inhibitors were initiated for 54 (42.5%), 36 (28.3%), and 37 (29.1%) patients, respectively. The numbers of patients positive for ANA, HBsAg, HBsAb, HBcAb, HCV antibody, HIV antibody, HTLV‐1 antibody, and T‐SPOT were 27 (21.3%), 0 (0%), 22 (17.3%), 20 (15.7%), three (2.4%), zero (0%), one (0.8%), and 4 (3.1%), respectively. The numbers of patients whose KL‐6 and β‐D‐glucan levels were higher than the reference values were seven (5.5%) and seven (5.5%), respectively. In the real‐world setting, it is sometimes unavoidable to use biologics for those patients with abnormal data although careful monitoring is necessary.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%